entertainment -WSS

entertainment

author：leisure time 2025-09-30 23:19:31 - browse：54433

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Readout Newsletter: Bluebird, CVS, Contineum

hotspot

WSS

Cognito secures funding to test medical device for Alzheimer's

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Creating egg and sperm cells from stem cells raises ethical issues

Time to name cancers by genetics, not organ of origin, expert says

Positive childhood experiences can help future health

Leading voice in opioid treatment defends methadone clinic system

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

Some dementia cases could be undiagnosed liver disease

Moonlake's readout produced a cash windfall. Risks remain

Argenx readies a blockbuster opportunity with drug for autoimmune disease

United colonoscopy coverage change 'may cost lives,' doctors say

Creating egg and sperm cells from stem cells raises ethical issues

United colonoscopy coverage change 'may cost lives,' doctors say

Cybersecurity threat forces Lurie Children's to take systems offline

George Santos makes 1st court appearance after pleading not guilty to 13 counts

UnitedHealth increases loan offers after Change Healthcare outage

Wikipedia

Leading voice in opioid treatment defends methadone clinic system

General Catalyst, Summa Health deal will turn on physician buy

General Catalyst, Summa Health deal will turn on physician buy

The real point of Kenneth Smith’s execution by nitrogen gas

Time to name cancers by genetics, not organ of origin, expert says

FDA drug safety: Singulair case shows systemic surveillance flaws

focus

hotspot

focus

entertainment